2Department of Medical Oncology, Acıbadem Mehmet Ali Aydınlar University, Adana-Turkey
3Department of Medical Oncology, Ersin Arslan Training and Research Hospital, Gaziantep-Turkey
4Department of Medical Oncology, Başkent University, Faculty of Medicine, Adana-Turkey DOI : 10.5505/tjo.2018.1829 OBJECTIVE
Small cell lung cancer (SCLC) is the most aggressive type of lung cancer. Platinum-etoposide chemotherapy combination is used as first line treatment. The aim of this trial is evaluate the effect of complete response rates and clinical features in patients with extensive stage (ES) SCLC.
METHODS
In this retrospective study, a total of 117 patients from four different oncology centers in Turkey between
2011 and 2017 were divided into 2 groups, namely, patients with complete response (group 1) and those
with no complete response (group 2) after platin-etoposide combination therapy.
RESULTS
The median age of the patients was 61 (range 38-81) years.The median follow-up time was 12 months
and 95 (81%) patients died. Progression-free survival (PFS) and overall survival (OS) were estimated,
respectively, as 8 and 13 months. Overall survival of group 1 patients was statistically significantly better
than the group 2 (16 versus 10 months respectively and p=0.00). The overall survival of patients who
had late recurrent disease (>6 mo.) was statistically significantly better than the early ones (<6 mo) (19
versus 14 months respectively and p=0,008).
CONCLUSION
Complete response and recurrent free time were the prognostic factors for ES SCLC patients in our study